Introduction:
Helicobacter pylori eradication remains a problematic issue. We are in an urgent need for finding a
treatment regimen that achieves eradication at a low cost and less side effect. Recent published results showing a high rate
of resistance and with clarithromycin-based treatment regimens. The aim of the study was to compare moxifloxacin therapy
and classic clarithromycin triple therapy in H. pylori eradication.
Methods:
This was a pilot study that enrolled 60 patients with helicobacter pylori associated gastritis. Diagnosis was done
by assessment of H. pylori Ag in the stool. The patients were randomly assigned to receive either moxifloxacin based therapy (Group A), or clarithromycin based therapy (Group B) for two weeks. We stopped the treatment for another two weeks
then reevaluation for cure was done.
Results:
90 % of patients had negative H. pylori Ag in the stool after 2 weeks of stoppage of the treatment in group A versus
66.7 % in Group B. None of the patients in both groups had major side effects.
Conclusion:
Moxifloxacin-based therapy showed higher eradication power and less resistance when compared to clarithromycin triple therapy.
Helicobacter pylori
eradication with proton pump inhibitor-based triple therapies and re-treatment with ranitidine bismuth citrate-based triple therapy